OrthoPediatrics Reports Record 2025 Revenue, Strong EBITDA Growth, and First Positive Q4 Free Cash Flow; Issues Positive 2026 Guidance

summarizeSummary

OrthoPediatrics Corp. announced record full year 2025 revenue of $236.3 million, a 15% increase, alongside significant Adjusted EBITDA growth and its first positive free cash flow quarter. The company also issued positive 2026 guidance, projecting continued revenue growth and breakeven free cash flow.

check_boxKey Events

• Record Full Year 2025 Revenue

  Reported record total annual revenue of $236.3 million for full year 2025, a 15% increase compared to $204.7 million in 2024.

• Strong Q4 2025 Performance

  Generated total revenue of $61.6 million for fourth quarter 2025, up 17% from $52.7 million in Q4 2024, with Adjusted EBITDA reaching $4.8 million compared to $3.0 million in Q4 2024.

• First Positive Free Cash Flow Quarter

  Achieved a historic milestone by generating $9.8 million of free cash flow in the fourth quarter of 2025, the first quarter of positive free cash flow in company history.

• Positive 2026 Financial Guidance

  Reiterated full year 2026 revenue guidance in the range of $262.0 million to $266.0 million (11% to 13% growth), projected Adjusted EBITDA of $25.0 million, and breakeven free cash flow for the full year.

auto_awesomeAnalysis

This 8-K finalizes OrthoPediatrics' strong financial performance for Q4 and full year 2025, building on preliminary revenue reports from January. The significant improvements in revenue, Adjusted EBITDA, and the achievement of the first-ever positive free cash flow quarter demonstrate operational efficiency and a clear path to sustained profitability. The positive 2026 guidance, including projected breakeven free cash flow for the full year, reinforces investor confidence in the company's growth trajectory and financial health.